<DOC>
	<DOCNO>NCT00815607</DOCNO>
	<brief_summary>The purpose study test safety investigational combination drug/immunotherapy treatment Stage III/IV melanoma .</brief_summary>
	<brief_title>Trial Intratumoral Injections INXN-3001 Subjects With Stage III IV Melanoma</brief_title>
	<detailed_description>This study examine effect oral Activator Ligand administration modulate time gene expression human IL-12 adenovirus-transduced dendritic cell inject tumor .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Males female race ≥ 18 year age ≤ 75 year age ; 2 . Unresectable Stage III C ( transit ) Stage IV melanoma ( M1a , M1b , M1c LDH ≤ 2x ULN ) , arise primary cutaneous , mucosal , subungual melanoma tumor thickness unknown primary site ; 3 . A minimum 23 accessible nonvisceral lesion ( long diameter ≤3 cm ) palpable tumorinvolved lymph node ( long diameter ≤5 cm ) intratumoral injection ( INXN3001 ) biopsies ; 4 . ECOG performance status 0 1 ; 5 . Patients without visible brain metastasis assess contrastenhanced MRI scan within 6 week prior receive study treatment ; 6 . Adequate baseline hematological organ function , assess laboratory value within 42 day ( 6 week ) prior study entry prior repeat treatment cycle INXN1001 follow : hemoglobin ≥ 10 g/L , granulocytes &gt; 2500/mm3 , lymphocytes &gt; 1000/ mm3 , platelet &gt; 100,000/ mm3 , serum creatinine &lt; 1.5 x ULN , AST , ALT , alkaline phosphatase &lt; 2.5 x ULN , LDH ≤ 2 x ULN , serum bilirubin &lt; 1.5 x ULN , absolute neutrophil &gt; 500/ mm3 ; 7 . An expected survival least approximately 6 month opinion investigator ( assess mainly performance status ) ; 8 . Females must postmenopausal surgically sterile practice effective contraception ; Men surgically sterile whose partner postmenopausal surgically sterile must practice effective contraception ; 9 . Normal coagulation parameter measure PT/PTT ; 10 . Signed , IRBapproved voluntary write informed consent . 1 . Active , acute viral , bacterial , fungal infection require specific therapy ; 2 . HIVinfection due concern ability mount effective immune response ; 3 . Active autoimmune disease require steroid ( &gt; 10 mg prednisolone comparable ) immunosuppressive therapy ; 4 . Patients detectable brain metastasis time screening ( within 6 week prior receive study treatment ) , assess contrastenhanced MRI scan ; 5 . Patients one lesion ( ) &gt; 3cm ( LD ) palpable , tumorinvolved lymph node ( ) &gt; 5 cm ( LD ) ; 6 . Patients hemoglobin &lt; 10 g/L ; 7 . Presence Stage IV visceral metastasis distant metastasis LDH &gt; 2 x ULN ; 8 . Patients previously treat INXN3001 INXN1001 ; 9 . Recipients organ allograft ; 10 . Other concurrent , clinically active malignant disease , exception cancer skin ; 11 . Less 30 day ( first dose study medication ) elapse since completion prior chemotherapy , hormonal therapy , radiotherapy , immunotherapy , first line therapy ; 12 . Clinically significant cerebrovascular disease ; 13 . History concurrent severe cardiac insufficiency ( New York Heart Association Class III IV ) coronary artery disease ; 14 . QTc interval &gt; 470 m screening ; 15 . Inability measure QT interval due conduction abnormality Bundle Branch Block ( leave right ) persistent cardiac arrhythmia e.g . atrial fibrillation , cardiac pacemaker ; 16 . Long QT syndrome family history sudden cardiac death young family member ; 17 . Concomitant use medication know affect ventricular repolarization ; 18 . Cardiac comorbidity leave ventricular ejection fraction &lt; 45 % , myocardial infarction , persistent angina , cardiac surgery within 3 month prior enrollment ; 19 . Uncontrollable hypertension ( &gt; 150 mm Hg systolic &gt; 100 mm Hg diastolic ) ; 20 . Acute medical condition ischemic heart lung disease may consider unacceptable anesthetic operative risk ; 21 . History current bleeding uncorrected clotting disorder ; 22 . Concurrent immunosuppressive therapy corticosteroid ( &gt; 10mg prednisolone comparable ) cyclosporin A ; 23 . Concurrent investigational treatment , treatment investigational treatment within past 30 day ( prior first dose study medication ) ; 24 . Concurrent medication metabolize CYP 3A4 pathway ; 25 . Females lactate pregnant ; 26 . A Body Mass Index ( BMI ) great equal 40 kg/m2 ; aa . Patients history hypersensitivity may relate component product , e.g . benzoic acid might relate INXN1001 , contain two benzene ring ; bb . Any medical psychiatric condition , opinion investigator , would unacceptably reduce safety delivery propose treatment , would preclude obtain voluntary informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>melanoma</keyword>
	<keyword>biologic</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>cancer</keyword>
</DOC>